Want to see FEMY full AI Analyst Report?
FEMY Stock Chart & Stats
$2.85
-$0.08(-2.11%)
At close: 4:00 PM EDT
$2.85
-$0.08(-2.11%)
Day’s Range― - ―
52-Week Range$2.02 - $22.22
Previous Close$3.71
Volume35.27K
Average Volume (3M)1.45M
Market Cap
$24.96M
Enterprise Value$17.38
Total Cash (Recent Filing)$1.44M
Total Debt (Recent Filing)$4.79M
Price to Earnings (P/E)―
Beta0.57
Next Earnings
Nov 17, 2026EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.56
Shares Outstanding8,375,027
10 Day Avg. Volume241,952
30 Day Avg. Volume1,452,870
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)3.88
Price to Sales (P/S)9.93
P/FCF Ratio-1.19
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.00Price Target Upside250.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.68
Revenue Forecast (FY)$3.77M
Bulls Say, Bears Say
Bulls Say
Improved Funding CapacityThe $30 million financing provides additional capital to fund operations, commercialization, and product development over the medium term. It improves near-term liquidity, although warrants and investor governance rights may reduce the benefit for existing shareholders.
Positive Gross MarginA roughly 50% gross margin indicates that Femasys’s products generate meaningful contribution after direct costs. If maintained while procedure volumes and account adoption expand, this margin can support operating leverage as the commercial base grows.
Consumable Women’s Health PortfolioFemasys addresses recurring gynecology and fertility procedures with disposable products, creating the potential for repeat purchases from clinical accounts. Its portfolio across diagnostics, intrauterine access, and assisted reproduction also provides multiple avenues for adoption.
Bears Say
Severe UnprofitabilityLosses remain extremely large relative to revenue, showing that the company has not reached the scale needed to support its cost base. This limits internal funding capacity and makes sustained commercialization dependent on significant revenue growth or external capital.
Persistent Cash BurnOperating and free cash flow deficits substantially exceed the current revenue base, indicating that operations are not self-funding. Continued investment in commercialization may therefore require additional financing, creating dilution or liquidity risks beyond the current period.
Weakened Balance SheetRising leverage and sharply reduced equity indicate diminished financial flexibility after ongoing losses. The weaker capital base can constrain product investment, increase dependence on financing markets, and leave shareholders more exposed to future dilution or restructuring.
Femasys News
FEMY FAQ
What was Femasys’s price range in the past 12 months?
Femasys lowest stock price was $2.02 and its highest was $22.22 in the past 12 months.
What is Femasys’s market cap?
Femasys’s market cap is $24.96M.
When is Femasys’s upcoming earnings report date?
Femasys’s upcoming earnings report date is Nov 17, 2026 which is in 72 days.
How were Femasys’s earnings last quarter?
Femasys released its earnings results on Aug 14, 2026. The company reported -$1.33 earnings per share for the quarter, missing the consensus estimate of -$1.31 by -$0.02.
Is Femasys overvalued?
According to Wall Street analysts Femasys’s price is currently Undervalued.
Does Femasys pay dividends?
Femasys does not currently pay dividends.
What is Femasys’s EPS estimate?
Femasys’s EPS estimate is -0.47.
How many shares outstanding does Femasys have?
Femasys has 8,375,027 shares outstanding.
What happened to Femasys’s price movement after its last earnings report?
Femasys reported an EPS of -$1.33 in its last earnings report, missing expectations of -$1.31. Following the earnings report the stock price went down -5.677%.
Which hedge fund is a major shareholder of Femasys?
Currently, no hedge funds are holding shares in FEMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Femasys
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.
FEMY Stock 12 Month Forecast
Average Price Target
$10.00
▲(250.88% Upside)
Technical Analysis
Retractable Technologies
―
Milestone Scientific
―
Precision Optics Corporation
―
NexGel Inc
―
―
Ownership Overview
15.04% Insiders
18.90% Mutual Funds
22.30% Other Institutional Investors
43.02% Public Companies and
Individual Investors